Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

(2019) Kohei Shitara et al.   Journal for ImmunoTherapy of Cancer

Novel anti-EPHA2 antibody, DS-8895a for cancer treatment

(2016) Jun Hasegawa et al.   CANCER BIOLOGY & THERAPY

EphA2 is a functional receptor for the growth factor progranulin

(2016) Thomas Neill et al.   JOURNAL OF CELL BIOLOGY

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

(2015) M. Duvic et al.   BLOOD

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer

(2015) P. D. Dunne et al.   CLINICAL CANCER RESEARCH

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

(2013) Jean-Pierre Delord et al.   EUROPEAN JOURNAL OF CANCER

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

(2012) Nidale Tarek et al.   JOURNAL OF CLINICAL INVESTIGATION

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer

(2011) William M. Merritt et al.   CANCER BIOLOGY & THERAPY

EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors

(2011) RONG Biao-xue et al.   CURRENT CANCER DRUG TARGETS

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

(2011) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Overexpression of EphA2 correlates with epithelial–mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients

(2011) Futao Hou et al.   MEDICAL ONCOLOGY

EphA receptor signaling—Complexity and emerging themes

(2011) Hui Miao et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc  Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

(2010) D. C. Delgado et al.   CANCER RESEARCH

Emerging strategies for EphA2 receptor targeting for cancer therapeutics

(2010) Manish Tandon et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Engineered therapeutic antibodies with improved effector functions

(2009) Tsuguo Kubota et al.   CANCER SCIENCE

Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer

(2009) J. M. Brannan et al.   CLINICAL CANCER RESEARCH

Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis

(2009) Pu Yang et al.   HEPATOLOGY RESEARCH

Eph-Ephrin Bidirectional Signaling in Physiology and Disease

(2008) Elena B. Pasquale   CELL